TrialBlood2020

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.

Andrew H Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.